Mecasermin
( DrugBank: Mecasermin / KEGG DRUG: Mecasermin, Mecasermin rinfabate )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 168 | Ehlers-Danlos syndrome | 1 |
| 265 | Lipodystrophy | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
168. Ehlers-Danlos syndrome
Clinical trials : 16 / Drugs : 22 - (DrugBank : 10) / Drug target genes : 11 - Drug target pathways : 103
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
265. Lipodystrophy
Clinical trials : 127 / Drugs : 137 - (DrugBank : 58) / Drug target genes : 28 - Drug target pathways : 99
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
299. Cystic fibrosis
Clinical trials : 1,826 / Drugs : 1,271 - (DrugBank : 246) / Drug target genes : 118 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
